Tuesday, Gilead Sciences, Inc. (GILD) announced that its subsidiary Kite Pharma's Yescarta has received approval from the FDA for a manufacturing process change that will reduce the median turnaround time or TAT for the therapy in the U.S. from 16 days to 14 days.
The median TAT is the time from leukapheresis, when a patient's T cells are collected to product release. After the T-cells are collected through leukapheresis, they are sent to Kite's specialized manufacturing facilities to be modified with a Chimeric Antigen Receptor. Once the individual therapy is prepared, the cells undergo thorough checks, preservation, and packaging before being returned to the hospital for infusion back into the patient.
The manufacturing process from leukapheresis to the delivery of the final product is continuous, making the timing and scheduling critical to the supply.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.